Top Banner
Break-through pain Break-through pain and it’s management and it’s management Slavica Lahajnar Institut of oncology Ljubljana
14

Break-through pain and it’s management Slavica Lahajnar Institut of oncology Ljubljana.

Dec 16, 2015

Download

Documents

Eileen Bradley
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Break-through pain and it’s management Slavica Lahajnar Institut of oncology Ljubljana.

Break-through pain Break-through pain and it’s management and it’s management

Slavica Lahajnar

Institut of oncology Ljubljana

Page 2: Break-through pain and it’s management Slavica Lahajnar Institut of oncology Ljubljana.

Break-through pain – patient’s statement

This sudden, strong pain brings me in anger and fear, my heart beats faster, I can not do anything. It takes from me the courage for life.

Patient with breast cancer and bone metastases

Page 3: Break-through pain and it’s management Slavica Lahajnar Institut of oncology Ljubljana.

Break-through pain – incidence and consequences

a half to two thirds of patients with chronic cancer pain

often unrecognized and untreated

worsens quality of life

economic burden

Portenoy RK et al. Pain 1999;81(1–2):129–134.Caraceni A et al. Palliat Med 2004;18:177–183.Fortner BV et al. J Pain 2002;3:38–44.

Page 4: Break-through pain and it’s management Slavica Lahajnar Institut of oncology Ljubljana.

Break-through pain - definition

transitory exacerbation of pain with relatively stable and adequately controlled baseline pain

spontaneous or provoked

Davies et all. Eur J Pain 2009;13: 331-338 Zappetella. Curr Opin Support Palliat Care 2009; 3: 1-6

Page 5: Break-through pain and it’s management Slavica Lahajnar Institut of oncology Ljubljana.

Break-through pain - characteristics

CauseSiteAnticipationOnset speedDurationIntensityFrequency

in 80% same as in baseline pain

in 75% one-sided

in 50 %

~ in 3 min.

~ 30 min

≥ 7 (VAS 0-10)

4x/day

in 80% same as in baseline pain

in 75% one-sided

in 50 %

~ in 3 min.

~ 30 min

≥ 7 (VAS 0-10)

4x/day

Portenoy et all. J Pain 2006; 7: 583-591

Page 6: Break-through pain and it’s management Slavica Lahajnar Institut of oncology Ljubljana.

Break-through pain - treatment

Treatment of basic illness:

RT, CT ..

Treatment of basic illness:

RT, CT ..

Non-pharmacologic methods

Non-pharmacologic methods

Change of lifestyle

Change of lifestyle

Psyhological support

Psyhological support

Interveningprocedures:

neuroaxilar inf., nevroablation

Interveningprocedures:

neuroaxilar inf., nevroablation

Pharmacotherapy: opioids,

non-opioids, additional drugs

Pharmacotherapy: opioids,

non-opioids, additional drugs

Multimodal treatment

Multimodal treatment

Page 7: Break-through pain and it’s management Slavica Lahajnar Institut of oncology Ljubljana.

Break-through pain – treatment with opioids

Treating cancer pain - idealTreating cancer pain - ideal

Treating cancer pain - currentTreating cancer pain - current

Page 8: Break-through pain and it’s management Slavica Lahajnar Institut of oncology Ljubljana.

Break-through pain - treatment

• morphinemorphine

Current treatment is NOT optimal

Davies A. BMJ 2009; in press

Page 9: Break-through pain and it’s management Slavica Lahajnar Institut of oncology Ljubljana.

Break-through pain - treatment

fentanylfentanyl

• oral transmucosal (lollipop), • buccal (tablet), • sublingual (tablet), • nasal (sprey), • inhaling

Page 10: Break-through pain and it’s management Slavica Lahajnar Institut of oncology Ljubljana.

Fentanyl – 40 years long history of analgetic activity

1968

intravenous fentanyl

1993

fentanyl patch

1998

oral transmucosal

fentanyl citrate

2006

fentanyl tablets (USA)

2008

fentanyl tablets(EU)

• pure agonist of mu-opioid receptors

• 80-100 x more potent than morphine

• without active metabolites

• very lipophylic: fast membrane crossing into CNS

Page 11: Break-through pain and it’s management Slavica Lahajnar Institut of oncology Ljubljana.

Abstral® - new innovative drug release technology

Rapid disintegration... Muco-adhesion... Rapid absorption.

Page 12: Break-through pain and it’s management Slavica Lahajnar Institut of oncology Ljubljana.

Fentanyl sublingual tablet (Abstral®)

rapid absorption into blood, high biologic availability (without first-pass metabolism in liver)

for opioid tolerant patients, already taking ≥ 60 mg of morphine or equivalent dose of other strong opioid

adverse events like in other strong opioids

Page 13: Break-through pain and it’s management Slavica Lahajnar Institut of oncology Ljubljana.

Abstral® - titration

ABSTRAL - significant improvement in pain intensity after 15 minutes, maximum dose of 800μg per episode of pain, patients should receive no more than 4 doses (8 tbl.)/day

first tablet second tablet

100 µg 100 µg

200 µg 100 µg

300 µg 100 µg

400 µg 200 µg

600 µg 200 µg

800 µg –

Different strengths available, the packaging is colour-coded and the tablets are differently shaped.

Abstral – Prescribing information

Page 14: Break-through pain and it’s management Slavica Lahajnar Institut of oncology Ljubljana.

Conclusions

multimodal treatment of break-through pain

tretment with opioids, which have rapid onset of action

sublingual fentanyl designed to match the temporal profile of breakthrough pain

effective dose should be titrated

Bredenburg S et al. Eur J Pharm Sci 2003;20:327–334.